ASML falls sharply after issuing a growth warning, while Goldman Sachs, Morgan Stanley, and Bank of America post better-than-expected quarterly earnings.

Trump has again threatened the multibillion-dollar pharmaceutical sector with high tariffs unless they move production to the U.S.

The company reports adjusted earnings of $2.77 a share for the second quarter, beating analysts’ estimates of $2.68.

House deals a blow to “Crypto Week,” ASML warns on 2026 growth, a promising Chinese weight-loss drug, and more news to start your day.

A promising experimental drug is one more sign of the impending disruption the booming Chinese biotech industry could bring to U.S. biopharma.

Boeing shares rise as the accident of Air India flight 171 doesn’t appear to have anything to do with aircraft design or manufacturing, while MicroStrategy and crypto-related stocks jump as Bitcoin sets a record high.

The company, formerly part of Johnson & Johnson, says it is taking steps “to accelerate profitable growth.”

Life sciences firm Waters will take on $4 billion in debt, and issue 39.2% of its shares to Becton Dickinson shareholders.

The charts show that the group is ready to rally.

The drugmaker has become a clear winner with its weight-loss drugs. Now, with a pill under development, the company should see earnings gains through the end of the decade.

Nvidia rises and pushes its market capitalization north of $4 trillion. It’s the first U.S. firm to reach and close above that level. Delta’s earnings beat analysts’ estimates.

Ultragenyx and partner Mereo BioPharma’s brittle bone disease trial will continue. Investors had wanted data good enough to end it early.

The exchange with the South American nation suggests the U.S. president also sees trade as a tool to influence other policies of foreign countries. 

Federal Reserve officials split over when to cut rates, Brazil vows response to 50% tariff, and more news to start your day.

Nvidia’s valuation crosses $4 trillion during Wednesday’s session, while AES stock rises sharply following a report that says the renewable power company is exploring its options amid takeover interest.

The deal is expected to close in the fourth quarter of 2025.

With few trade deals secured to date, that leaves just three weeks to secure pacts with dozens of countries.

The franchise drug for autoimmune disorders such as dermatitis could face a challenger: A candidate from Apogee Therapeutics.

Shares of Novavax, Pfizer, and other peers were also seeing gains on Tuesday.

Both well-established and small, clinical-stage pharma companies are investing heavily to be able to someday compete with Lilly and Novo.